Five Prime Therapeutics Inc (NASDAQ:FPRX) – Equities research analysts at Jefferies Financial Group issued their Q2 2020 earnings per share estimates for shares of Five Prime Therapeutics in a report issued on Wednesday, November 6th. Jefferies Financial Group analyst E. Yang forecasts that the biotechnology company will post earnings of ($0.81) per share for the quarter. Jefferies Financial Group also issued estimates for Five Prime Therapeutics’ Q3 2020 earnings at ($0.82) EPS.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The firm had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $4.33 million.
A number of other research firms have also issued reports on FPRX. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a research note on Thursday. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Guggenheim lowered Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. Five Prime Therapeutics currently has an average rating of “Hold” and an average target price of $14.40.
Shares of NASDAQ FPRX traded up $0.01 during trading on Friday, reaching $3.89. 382,100 shares of the stock traded hands, compared to its average volume of 371,306. Five Prime Therapeutics has a 52-week low of $3.22 and a 52-week high of $13.97. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.87 and a quick ratio of 6.87. The company has a 50-day moving average of $4.17 and a 200-day moving average of $6.31. The stock has a market capitalization of $151.17 million, a P/E ratio of -0.94 and a beta of 2.55.
In other Five Prime Therapeutics news, major shareholder Bvf Partners L. P/Il bought 16,000 shares of the firm’s stock in a transaction on Friday, October 4th. The shares were acquired at an average cost of $3.74 per share, for a total transaction of $59,840.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 525,070 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $3.75 per share, for a total transaction of $1,969,012.50. The disclosure for this purchase can be found here. Insiders acquired a total of 2,352,563 shares of company stock worth $9,131,479 over the last 90 days. Corporate insiders own 7.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in Five Prime Therapeutics by 86.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock worth $6,930,000 after acquiring an additional 533,100 shares during the last quarter. Man Group plc boosted its holdings in shares of Five Prime Therapeutics by 95.9% in the 2nd quarter. Man Group plc now owns 1,160,411 shares of the biotechnology company’s stock worth $6,997,000 after purchasing an additional 568,017 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Five Prime Therapeutics by 32.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 321,907 shares of the biotechnology company’s stock worth $1,947,000 after purchasing an additional 78,404 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Five Prime Therapeutics by 1,167.3% in the 2nd quarter. Morgan Stanley now owns 258,317 shares of the biotechnology company’s stock worth $1,558,000 after purchasing an additional 237,933 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of Five Prime Therapeutics in the 2nd quarter worth about $286,000. Institutional investors and hedge funds own 74.41% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Further Reading: Channel Trading
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.